Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need

Blood (2025) 146 (Supplement 1): 2756.

https://doi.org/10.1182/blood-2025-2756

Published: 2025

Journal Articles

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 565.

https://doi.org/10.1182/blood-2025-565

Published: 2025

Journal Articles

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

Blood (2025) 146 (Supplement 1): 5341.

https://doi.org/10.1182/blood-2025-5341

Published: 2025

Journal Articles

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

William Johnson, Joseph Rocco, Rikita Patel, Adrianna Herskovits, Elena Mead, Jae Park, Alison Moskowitz, Zachary Epstein-Peterson, Robert Stuver, Neil Bapodra, Rabeya Molla, Andrew Intlekofer, Jennifer Lue, Lia Palomba, Ariela Noy, Jasmine Zain, Colette Owens, Lynnette Henshaw, Paola Ghione, Efrat Luttwak, Pallawi Torka, Andrew Zelenetz, Philip Caron, Anita Kumar, Lorenzo Falchi, Natasha Galasso, Paul Hamlin, Alexander Boardman, Kevin David, Raphael Steiner, Nivetha Ganesan, Tiffany Chang, Zainab Shahid, Wenbin Xiao, Annamaria Ballweg, Alina Markova, Mark Geyer, Lauren Banaszak, Roni Shouval, Sergio Giralt, Gregory Goldgof, Jodi Mones, Jeffrey Zwicker, Rekha Parameswaran, Avi Leader, Cy R. Wilkins, Simon Mantha, Jeffrey Cohen, Jessica Durkee-Shock, Matthew Sedlock, Bita Shakoory, Irini Sereti, Miguel-Angel Perales, Gilles Salles, Santosha Vardhana, Joseph Oved, Steven Horwitz

Blood (2025) 146 (Supplement 1): 2996.

https://doi.org/10.1182/blood-2025-2996

Published: 2025

Journal Articles

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Blood (2025) 146 (Supplement 1): 7090.

https://doi.org/10.1182/blood-2025-7090

Published: 2025

Journal Articles

MSK-impact heme accurately reproduces diffuse large B-cell (DLBCL) dlbclass cluster classification across clinical scenarios, including diagnosis, relapse, and histological transformation

Blood (2025) 146 (Supplement 1): 1766.

https://doi.org/10.1182/blood-2025-1766

Published: 2025

Journal Articles

Non-hematotoxic Tim-3/CD70 dual-targeting CAR T cells promote potent anti-leukemia activity against acute myeloid leukemia

Sophia Chen, Adhithi Rajagopalan, Katerina Su, Anastasia Kousa, Preet Kaur, Ryan Lee, Jacob Fischman, Alyssa Massa, Dylan Manuele, Brandon Ng, Alexander Boardman, Susan DeWolf, Judith Hecker, Peter Fridy, Michael Rout, Brian Chait, Marcel van den Brink, Scott James

Blood (2025) 146 (Supplement 1): 2345.

https://doi.org/10.1182/blood-2025-2345

Published: 2025

Journal Articles

Insights in the management of older adults with mantle cell lymphoma amidst a changing therapeutic landscape: Lessons from a 25-year institutional experience

Blood (2025) 146 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2025-1811

Published: 2025

Journal Articles

Pre-existing cognitive impairment is associated with reduced long-term survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Blood (2025) 146 (Supplement 1): 6296.

https://doi.org/10.1182/blood-2025-6296

Published: 2025

Journal Articles

Respiratory syncytial virus (RSV) infection after CAR T-cell therapy

Blood (2025) 146 (Supplement 1): 1079.

https://doi.org/10.1182/blood-2025-1079

Published: 2025

Journal Articles

Transformed Waldenström macroglobulinemia is associated with poor outcomes and chemorefractory disease

Blood (2025) 146 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2025-3573

Published: 2025

Journal Articles

Combined mosunetuzumab and zanubrutinib for the treatment of patients with newly diagnosed high-burden follicular lymphoma: First results of the multicenter phase 2 mithic-FL2 trial

Blood (2025) 146 (Supplement 1): 463.

https://doi.org/10.1182/blood-2025-463

Published: 2025

Journal Articles

Impact of holding therapy prior to apheresis on outcomes following CD19 CAR-T cell therapy in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 6328.

https://doi.org/10.1182/blood-2025-6328

Published: 2025

Journal Articles

Integrated dissociated and spatial single-cell profiling reveals that HDAC inhibition restores anti-PD-1 sensitivity in Hodgkin lymphoma by disrupting monocyte-Hodgkin-reed-sternberg cell-driven immunosuppressive niches.

Blood (2025) 146 (Supplement 1): 150.

https://doi.org/10.1182/blood-2025-150

Published: 2025

Journal Articles

Efficacy and safety of zanubrutinib in patients with non-IgM lymphoplasmacytic lymphoma

Mika Geva, Michelle Okwali, Lorenzo Falchi, Ahmet Dogan, Shenon Sethi, Alexander Boardman, Paul Hamlin, Paola Ghione, Colette Owens, Gilles Salles, Lia Palomba, Zachary Epstein-Peterson

Blood (2025) 146 (Supplement 1): 5374.

https://doi.org/10.1182/blood-2025-5374

Published: 2025

Journal Articles

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

Blood (2025) 146 (Supplement 1): 3723.

https://doi.org/10.1182/blood-2025-3723

Published: 2025

Journal Articles

Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study

Blood (2025) 146 (Supplement 1): 3605.

https://doi.org/10.1182/blood-2025-3605

Published: 2025

Journal Articles

BTKi in the peri-infusion period in lymphoma patients receiving CD19 CAR T cell therapy

Blood (2025) 146 (Supplement 1): 4492.

https://doi.org/10.1182/blood-2025-4492

Published: 2025

Journal Articles

Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial

Blood (2025) 146 (Supplement 1): 1971.

https://doi.org/10.1182/blood-2025-1971

Published: 2025

Journal Articles

Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity

Blood (2025) 146 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2025-1959

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

MSK-impact heme accurately reproduces diffuse large B-cell (DLBCL) dlbclass cluster classification across clinical scenarios, including diagnosis, relapse, and histological transformation

Non-hematotoxic Tim-3/CD70 dual-targeting CAR T cells promote potent anti-leukemia activity against acute myeloid leukemia

Insights in the management of older adults with mantle cell lymphoma amidst a changing therapeutic landscape: Lessons from a 25-year institutional experience

Pre-existing cognitive impairment is associated with reduced long-term survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Respiratory syncytial virus (RSV) infection after CAR T-cell therapy

Transformed Waldenström macroglobulinemia is associated with poor outcomes and chemorefractory disease

Combined mosunetuzumab and zanubrutinib for the treatment of patients with newly diagnosed high-burden follicular lymphoma: First results of the multicenter phase 2 mithic-FL2 trial

Impact of holding therapy prior to apheresis on outcomes following CD19 CAR-T cell therapy in large B-cell lymphoma

Integrated dissociated and spatial single-cell profiling reveals that HDAC inhibition restores anti-PD-1 sensitivity in Hodgkin lymphoma by disrupting monocyte-Hodgkin-reed-sternberg cell-driven immunosuppressive niches.

Efficacy and safety of zanubrutinib in patients with non-IgM lymphoplasmacytic lymphoma

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study

BTKi in the peri-infusion period in lymphoma patients receiving CD19 CAR T cell therapy

Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial

Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only